At the MedCity INVEST conference May 20-21 in Chicago, the startups will take part in the Pitch Perfect contest, pitching their technology and services to investor judges.
MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under a new joint venture the biotech is forming with Hologen, a generative AI startup. The joint venture has up to $230 million in committed capital; MeiraGTx gets additional cash for its pipeline.
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.
Charity Tarn, an investor with Arboretum Ventures, will be one of the investor judges for the Pitch Perfect contest at INVEST in Chicago May 20-21. Register today!
Sofinnova Partners aims to invest in 50 to 60 new companies in the life sciences. The infusion of new capital brings the VC firm’s assets under management to more than €4 billion.
Eikon Therapeutics’ lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class.
Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health. Accepted applicants will be admitted to Altitude Lab, the Salt Lake City biotech accelerator formed by Recursion Pharmaceuticals.
Innovative sterilization cases and trays are instrumental in reducing infection risk in medical settings. Learn notable things about them and their makers.
We're looking for biopharma startups focused on infectious diseases, medtech/diagnostics startups supporting chronic disease management, and health tech startups seeking to improve care navigation and coordination and developing AI tech.
If you rely on federal grants as your sole means of support, you’re tying your destiny to forces outside your control. There are other roads to success in health and medical research. By pursuing them, you might gain more freedom, fewer administrative hurdles, and the chance to save lives faster.
Check out news from Oral Genome, Junevity, Coral, Keragon, and more.
The healthcare investor conference, scheduled for May 20 and 21 at the Willis Tower in Chicago, combines panel discussions, networking opportunities, and a startup pitch contest. Register today!
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
The structure of Atalanta Therapeutics’ RNA interference drugs enables them to distribute broadly and deeply into brain tissue. Lead programs for Huntington’s disease and a rare inherited form epilepsy are on track to enter the clinic this year.
China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why biotech in China is booming as well as therapeutic areas where he sees promising science.
In this second of a two-part article, we'll cover common obstacles and offer insights on how to overcome these barriers to achieve success in the healthcare market.
Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.